National Science Foundation

The Kentucky Science and Engineering Foundation (KSEF) is dedicated to fostering innovation and enhancing economic growth in the Commonwealth of Kentucky. Established to support research and development activities, KSEF aims to build a robust pipeline of new ideas and technologies. By investing in various scientific initiatives, the foundation seeks to promote advancements that can contribute to the overall development of the state's economy and scientific landscape.

Amphix Bio specializes in the development of therapeutic materials aimed at advancing regenerative medicine. The company focuses on creating nanofiber materials that replicate the structure and dynamic properties of human tissues. By integrating biological signals into these materials, Amphix Bio effectively guides cells to initiate regenerative processes. This innovative approach enables the development of therapies for repairing various tissues, including bone, cartilage, muscle, cardiovascular tissues, and nervous system components such as the brain and spinal cord. With expertise in materials science, stem cell biology, biomolecular design, engineering, medical physics, and informatics, Amphix Bio seeks to translate its promising preclinical and clinical trial results into viable treatment options.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

The Wistar Institute is a leading independent biomedical research institution dedicated to advancing medical knowledge through innovative research and training. Established as the first of its kind in the United States, it has grown from an anatomical teaching museum into a prominent center for basic biomedical research. Designated as a National Cancer Institute Cancer Center in 1972, The Wistar Institute focuses on critical areas such as cancer, immunology, and infectious diseases. Its groundbreaking discoveries have contributed to the development of vaccines for diseases like rabies, rubella, and rotavirus, as well as the identification of genes related to breast, lung, and prostate cancer. The Institute promotes a collaborative research environment aimed at addressing some of the most pressing challenges in the biomedical field.

Amplified Sciences LLC is a molecular diagnostics company based in West Lafayette, Indiana, that specializes in the early detection of debilitating diseases, including pancreatic cancer and kidney disease. The company utilizes an ultra-sensitive molecular sensing technology, licensed exclusively from Purdue University, which allows for the detection of disease markers at the single-molecule level. This technology is versatile and disease state agnostic, enabling accurate diagnosis using bodily fluids such as urine and saliva. Amplified Sciences has developed a point-of-care system that combines sensing and assay methods with low-cost biospecimen collection devices, facilitating scalability and accessibility in healthcare settings. Their first application focuses on the early detection of pancreatic cancer, addressing a significant unmet medical need and offering a favorable reimbursement pathway. With a working prototype and published proof of concept data, Amplified Sciences aims to provide healthcare professionals with innovative diagnostics that can operate with a single sample on one instrument.

MelliCell is a biotechnology company focused on addressing chronic diseases through innovative tissue engineering technology that targets fat cells. The company’s platform enables the conversion of human stem cells into mature fat cells, facilitating their accelerated growth to sizes that surpass conventional limits. This technology aims to shrink fat cells and improve metabolic health, making it applicable for treating conditions such as obesity, diabetes, aging, oncology, and inflammation. MelliCell’s experienced team is developing oral small molecules that not only decrease fat mass but also reverse disease hallmarks while preserving lean mass. The efficacy of MelliCell’s technology has been recognized through various awards and partnerships with leading biopharmaceutical firms, highlighting its potential to enhance health outcomes and quality of life for individuals worldwide.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

Astria Biosciences, based in Pittsburgh, specializes in developing innovative diagnostic and therapeutic solutions for cerebrovascular diseases. The company focuses on addressing neurosurgical challenges through molecular biology, advanced analytics, and small-molecule inhibitors, aiming to provide non-surgical alternatives for neurovascular conditions where surgery is currently the primary option.

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for a variety of debilitating conditions. The company employs a unique approach that combines established technologies in innovative ways to address well-defined disease mechanisms. By modularly applying these proven technologies, Remedium Bio focuses on creating localized and targeted therapies centered on clinically validated molecules and pathways. Its pipeline includes leading gene therapy candidates in multiple fields, such as rheumatology, endocrinology, and neurology, aimed at providing effective treatments for a range of immune, age-related, and metabolic disorders.

The University of Wisconsin-Madison is a prominent research institution and land-grant university located in Madison, Wisconsin. It provides a comprehensive range of educational offerings, including liberal arts studies and professional programs, catering to a diverse student population. The university's expansive campus features approximately 600 undergraduate and graduate majors, along with over 9,000 courses that encompass a wide array of disciplines, from accounting to zoology. In addition to its academic programs, UW-Madison fosters a vibrant student life, offering various activities and organizations that enhance the educational experience.

Nexilico, Inc. is an early-stage biotechnology firm established in 2017 and headquartered in Albany, California. The company specializes in advancing microbiome and precision medicine through the development of innovative predictive computational platforms. These platforms enhance drug design and development, focusing on improving clinical outcomes in therapeutics. By pioneering next-generation in silico microbiome technologies, Nexilico aims to deepen the scientific understanding of microbiomes and their impact on health and disease. This knowledge enables Nexilico to create novel microbiome-based approaches that support clients in optimizing drug development processes and outcomes.

Oregon State University, founded in 1868, serves as the state’s Land Grant university and is distinguished by its Sea Grant, Space Grant, and Sun Grant designations, making it one of only two U.S. universities to hold this combination. It is recognized for its research excellence and community engagement, holding the Carnegie Foundation's top designation for research institutions. With a diverse student body of over 26,000 from across Oregon and more than 100 countries, Oregon State offers over 200 undergraduate and 80 graduate degree programs, including more than 30 online degrees through Oregon State Ecampus. The university operates 12 colleges, 15 Agricultural Experiment Stations, and 35 county Extension offices, as well as facilities such as the Hatfield Marine Sciences Center and OSU-Cascades. Oregon State's economic impact extends across all 36 counties in Oregon, contributing $2.06 billion to the state's economy. The university is noted for its strong programs in fields including conservation biology, agricultural sciences, nuclear engineering, and pharmacy, attracting high-achieving students committed to making a positive difference in society.

Oregon State University, founded in 1868, serves as the state’s Land Grant university and is distinguished by its Sea Grant, Space Grant, and Sun Grant designations, making it one of only two U.S. universities to hold this combination. It is recognized for its research excellence and community engagement, holding the Carnegie Foundation's top designation for research institutions. With a diverse student body of over 26,000 from across Oregon and more than 100 countries, Oregon State offers over 200 undergraduate and 80 graduate degree programs, including more than 30 online degrees through Oregon State Ecampus. The university operates 12 colleges, 15 Agricultural Experiment Stations, and 35 county Extension offices, as well as facilities such as the Hatfield Marine Sciences Center and OSU-Cascades. Oregon State's economic impact extends across all 36 counties in Oregon, contributing $2.06 billion to the state's economy. The university is noted for its strong programs in fields including conservation biology, agricultural sciences, nuclear engineering, and pharmacy, attracting high-achieving students committed to making a positive difference in society.

North Carolina A&T State University is so many things to so many people, both in our state and around the country. North Carolina A&T State University is an HBCU. We are a top-flight research university, the largest historically black university (HBCU) in the country, the #1 producer of degrees awarded to African Americans in North Carolina and nationally recognized or our excellence in science, technology, mathematics and engineering (STEM) education. We are a diverse community, bound by intense pride and tradition, with fiercely loyal alumni who hold positions of importance and influence in companies and government agencies across the state, the country and the world. We are achievers, driven by a curious, limitless, fearless spirit that fuels discovery and innovation, resulting in 41 patents issued based on our research, as well as numerous spin-off and start-up companies. We are inclusive and welcoming, with students from many backgrounds and cultures, every part of our state, our nation and countries around the globe. We are passionate, driven by a desire to do more, be more and make more of a difference. Since we opened our doors in 1892, we have focused on giving every student the hands-on opportunities, core knowledge and global perspective that will lead them to make real and lasting change in their lives and the lives of others. At N.C. A&T, we have so much to be proud of, and you can learn more about those "Points of Pride" here. You can also use the links below to learn more about what makes N.C. A&T unique, from our leadership and history to our many rankings and recognitions.

Protabit is a protein engineering company focused on developing innovative solutions for industrial, agricultural, and healthcare applications. The company utilizes a proprietary platform that integrates computational modeling, high-throughput screening, and directed evolution to enhance the diversity of protein sequences. This advanced approach allows Protabit to create novel proteins tailored to meet specific client needs. The company's efforts are further strengthened through a strategic partnership with the Monsanto Company and the California Institute of Technology, positioning Protabit at the forefront of the protein design field.

Bespoke Biotherapeutics provides an effective natural immune response and overcomes the limitations of currently approved immunotherapies against cancer by inventing novel, customised living drugs called engineered B-cell therapeutics. They offer customised B-cell sourcing, isolation, activation, culture expansion, and non-viral genetic engineering methodologies uniquely suited to optimise commercial B-cell products for infusion.

OncoSTING LLC, established in 2018 and headquartered in Baltimore, Maryland, specializes in developing innovative therapies for bladder cancer. The company's primary focus is on creating a novel treatment that combines the potency of standard Bacillus Calmette-Guérin (BCG) immunotherapy with long-lived delivery of potent Stimulator of Interferon Genes (STING) agonists. This approach aims to enhance therapeutic efficacy while reducing adverse events associated with traditional BCG treatments, ultimately working towards curing bladder cancer.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the underlying causes of these conditions, particularly immune evasion and drug resistance. Its primary focus is on creating market-disruptive biologics for recurrent and drug-resistant cancers, specifically addressing the needs of patients with recurrent metastatic breast cancer. By concentrating on these critical areas, Creative BioTherapeutics seeks to enable medical professionals to provide effective treatments for both adult and childhood cancers, potentially leading to tumor regression and improved patient outcomes.

ViQi is a software-as-a-service company specializing in scientific image analysis. It offers a customizable platform that enables users to tailor services for data storage and analysis to meet their specific requirements. The company provides tools for image processing and informatics across various sectors, including life sciences, construction, and agriculture. ViQi's platform features a bio-image semantic query system, which facilitates module development and assists with intranet deployment. Additionally, it supports the hosting of image collections, allowing clients to view, investigate, share, and store complex data and images efficiently. This comprehensive approach enables swift results and enhances the discovery process for users in diverse fields.

EzraBio is a biotechnology company focused on enhancing ribosome profiling for researchers across various biological samples. The company specializes in RNA adenylation technology, which facilitates efficient and rapid cDNA library construction. By offering streamlined services that encompass sample preparation and deep sequencing, EzraBio aims to simplify the ribosome profiling process. This innovative approach allows medical professionals to uncover hidden coding potential, analyze translational responses, identify tumor-associated antigens, and advance mRNA therapeutics. Through its cutting-edge solutions, EzraBio supports researchers in their quest to deepen understanding of complex biological mechanisms.

Simmbion is a biotechnology company that develops innovative therapies using symbionts, which are microorganisms that live harmoniously within the human body. Their core business involves creating therapeutic agents within the body itself, eliminating the need for complex manufacturing processes, frequent injections or infusions, temperature-sensitive storage, and high associated costs. This patient-centric approach aims to enhance healthcare outcomes while minimizing risks of infection or immune rejection. Simmbion's technology is adaptable across various health applications, universally compatible with human immunity, long-lasting (a single injection can last up to 12 weeks), and resistant to supply chain disruptions, making it an affordable and equitable solution for diverse patient populations worldwide.

Cryptyx Bioscience is a biopharmaceutical company focused on discovering new therapeutic natural products from bacteria without the use of genetics or cloning. Their innovative platform aims to activate silent biosynthetic gene clusters within bacteria, allowing them to unlock the full potential of culturable microbes. By employing a bioactivity-first approach, Cryptyx seeks to rapidly identify new antibiotics and antiviral drugs, addressing critical needs in combating infectious diseases prioritized by health organizations. The company's technology is designed to provide a broad range of medical services and therapeutic applications, ultimately enhancing treatment options for patients.

PETL Fluidics is an operator of a microfluidics platform focused on laboratory research. The company specializes in controlling, managing, and experimenting within microfluidic environments. Its platform enables laboratories to conduct various applications, including chemical reactions, cell and organoid culture, advanced imaging, and mechanobiology. By providing custom-designed microfluidics, PETL Fluidics supports researchers in achieving precise control over experimental conditions, thus enhancing the capabilities of scientific inquiry and innovation.

Secure Food Solutions Inc., established in 2014 and based in Martin, Tennessee, specializes in enhancing global food safety by developing advanced detection technologies for toxins, pathogens, and contaminants. The company's core offering is a patented hyperspectral imaging technology designed to swiftly identify corn contaminated with aflatoxin, aiming to improve food quality and safety worldwide.

Levisonics is a manufacturer of innovative blood coagulation instruments that specialize in non-contact analysis for both blood coagulation and fluid quality control testing. The company’s technology enables users to assess bleeding and thrombosis risks through non-invasive fluid rheological measurements. In addition to its applications in medical diagnostics, Levisonics' products are also employed in real-time monitoring of the quality of food, liquid, and gel products during production or processing. By providing a non-contact method for these critical analyses, Levisonics aims to enhance safety and quality in various industries.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

Amphix Bio specializes in the development of therapeutic materials aimed at advancing regenerative medicine. The company focuses on creating nanofiber materials that replicate the structure and dynamic properties of human tissues. By integrating biological signals into these materials, Amphix Bio effectively guides cells to initiate regenerative processes. This innovative approach enables the development of therapies for repairing various tissues, including bone, cartilage, muscle, cardiovascular tissues, and nervous system components such as the brain and spinal cord. With expertise in materials science, stem cell biology, biomolecular design, engineering, medical physics, and informatics, Amphix Bio seeks to translate its promising preclinical and clinical trial results into viable treatment options.

Cytocybernetics is a biotechnology company that specializes in cellular electrophysiology. The company has developed the Cybercyte, a powerful and user-friendly plug-and-play dynamic clamp system designed to facilitate advanced research. In addition to its innovative products, Cytocybernetics offers a comprehensive range of contract research organization (CRO) services. These services include FDA-mandated drug safety screening, as well as custom electrophysiology, modeling, and analysis tailored to meet the specific needs of its clients. By providing these solutions, Cytocybernetics supports a variety of cellular research and product development initiatives.

GeniPhys LLC is a medical technology company founded in 2014 and headquartered in Zionsville, Indiana. The company focuses on the commercialization of standardized tunable collagen polymers, known as collymers, and collagen-fibril materials for various research and medical applications. GeniPhys manufactures research-grade collymers and polymerization reagents that allow for user customization of 3D collagen-fibril matrices, which are essential for developing in-vitro tissue systems used in drug discovery, toxicity testing, and fundamental cell research. Its product offerings include polymerization kits, solutions, buffers, and supplements, all available online. GeniPhys's innovative technology supports the design and fabrication of collagen materials that promote tissue restoration and regeneration, aiding medical researchers in exploring new applications for regenerative tissue replacements and pharmaceutical therapies.

Isolere Bio, established in 2018, is a healthcare company specializing in biotherapeutic purification. Its core business involves simplifying and optimizing the manufacturing process of monoclonal antibodies and Adeno-Associated Viruses (AAVs) using Tangential Flow Filtration (TFF) technology. This streamlined approach aims to enhance global access to these vital drugs and research tools, while facilitating a seamless transition from laboratory-scale production to industrial-level output.

OmicsCraft offers customers access to a customised data analytics pipeline and a sample-to-solution service. They offer cloud-based platforms that allow them to build analytics pipelines for omic data preprocessing, mass spectrometric-based metabolite identification, differential analysis of metabolite profiles, and multi-omics integration.

Auctus Biologics is a pre-clinical biotechnology company focused on developing innovative antibody mimetics for therapeutic and diagnostic uses. The company is engaged in creating a ribose-binding protein designed to bind clinical targets with a high affinity, similar to monoclonal antibodies, while overcoming the limitations associated with traditional antibodies. These limitations include instability, the need for costly cold-chain management, and challenges with administration in extreme environments such as the gastrointestinal tract. By engineering their mimetic scaffold to withstand repeat boiling cycles, Auctus Biologics aims to facilitate advanced treatment options that reduce costs and improve the accessibility of biologic therapies for patients.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

MBF Therapeutics, Inc. is a veterinary oncology company based in Ambler, Pennsylvania, focused on developing and commercializing innovative therapies for cancer treatment in dogs and cats. The company specializes in targeted immunotherapies and small molecule drugs that effectively disrupt tumor cell metabolism while preserving healthy cells and organs. Its product portfolio includes MBFT-101, a combination therapy for sarcomas and lymphoma, featuring a proprietary polyamine transport inhibitor and a potent inhibitor of ornithine decarboxylase, as well as MBFT-102, an immunotherapy based on the tumor suppressor/cytokine mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics employs a proprietary DNA vaccine platform and delivery system to develop immunotherapeutic vaccines aimed at enhancing protective immunity against infectious diseases in companion animals and livestock. The company maintains a strategic partnership with the Lankenau Institute for Medical Research to further advance its research and development initiatives.

Aqueduct Fluidics, founded in 2019 and headquartered in Philadelphia, PA, specializes in developing automation solutions tailored for physical and life sciences research on a laboratory benchtop. The company offers a software automation tool designed to streamline workflows and integrate various hardware components, thereby accelerating the development process. Its platform enables users to create automation scripts and features an intuitive interface for controlling and visualizing hardware status. Additionally, Aqueduct Fluidics simplifies system integration by addressing complex aspects such as communication protocols, command timing, user interfaces, and data persistence. This comprehensive approach equips developers with the necessary tools and resources to effectively develop, test, and deploy automation programs for benchtop-scale applications.

Vulcan Biologics, established in 2019 and based in Irvine, California, specializes in biotechnology solutions for modulating microbiomes. Its core platform employs bacteriophages, which selectively target and alter specific gut bacteria without affecting the human host, aiming to achieve stable and persistent changes in the microbiome. This approach is primarily focused on treating gluten-related disorders, including gluten sensitivity and celiac disease.

Zymosense is a company focused on developing innovative solutions for enzyme screening and characterization. It offers an automated aqueous two-phase extraction method that enables the low-cost and scalable sorting of chiral-pure single-walled carbon nanotubes. This technology includes a proof-of-concept demonstration for automating the NIST-developed ATP system, enhancing the separation process of these nanotubes. Additionally, Zymosense's enzyme screening platform utilizes advanced plate and handheld readers that employ fluorescent nanoparticles in target enzyme substrates to generate activity probes. This approach provides research scientists and biotechnology companies with rapid evaluation, discovery, and design capabilities for new enzymes, promoting advancements in various industrial applications.

Synvivia, Inc. is a biotechnology company founded in 2016 and based in Berkeley, California. The company specializes in developing synthetic biology products, particularly ON-OFF switches for genetically engineered organisms. These protein switches are regulated by small molecules, allowing for precise control of biological functions within the organisms. Synvivia's innovations enable the creation of engineered organisms that can be utilized in healthcare, specifically for diagnosing diseases and enhancing treatment options. Additionally, the company is focused on generating biosensors to identify and improve enzymatic activities, thereby facilitating more effective disease management.

Cision Vision is a biotechnology company focused on developing and supplying innovative imaging medical products specifically designed for the examination of lymph nodes. Its advanced imaging devices enable pathologists to visualize, scan, and record lymph nodes in real-time with high contrast, eliminating the need for injections or radiation. By providing pathologists with tools that enhance the accuracy and consistency of pathology grossing, Cision Vision aims to modernize the field and improve the quality of care delivered to patients.

Spekciton Biosciences specializes in biophotonic measurement systems and services aimed at enhancing agricultural performance and sustainability. The company develops innovative technologies that enable the rapid and precise detection of plant stress and viability, providing farmers with essential insights for improving crop management. Additionally, Spekciton offers biosensors designed to quickly identify soil and water contamination, supporting environmental health and agricultural productivity. Through its advanced measurement solutions, the company contributes to a better understanding of bioprocesses, ultimately aiding in the cultivation of resilient and sustainable crops.

Aracari Biosciences is focused on advancing drug discovery through its innovative 3D Vascularized Micro-Organ platforms. These platforms enhance the biological authenticity of pre-clinical testing by providing a realistic environment for evaluating the efficacy of lead compounds against tumors in a three-dimensional context. Aracari's technology enables real-time imaging of vessel morphology and adapts to various physiological scenarios, allowing for the perfusion of fluorophore-tagged dextrans of differing molecular weights. This unique approach helps pharmaceutical companies improve decision-making processes and accelerates the overall development of new drugs.

Envivo Bio develops a non-invasive device that collects microbiome samples from all regions of the human gastrointestinal tract. The company is based in San Carlos, California.

Soil Culture Solutions, LLC, founded in 2014 and based in Tampa, Florida, specializes in innovative genetic alteration technology. The company focuses on developing citrus trees using CRISPR editing techniques to enhance their resistance to severe diseases that threaten the citrus industry. Soil Culture Solutions holds exclusive licenses to patents from community universities, enabling it to employ precision breeding methods to effectively combat these critical infections in citrus crops.

Felix Biotechnology, Inc. is a San Francisco-based company founded in 2019 that specializes in developing biotherapeutics to combat microbial challenges in human health. The company focuses on creating treatments for antibiotic-resistant strains of bacteria and fungi, aiming to address the urgent need for effective management of infectious diseases. By accelerating the deployment of novel biotherapeutics, Felix Biotechnology seeks to provide healthcare professionals with precise and effective tools to tackle these pressing health issues.

Biochip Labs is a company based in Cleveland, Ohio, founded in 2019. It specializes in providing laboratory testing services focused on blood disorders, particularly sickle cell disease and thalassemia. The company offers a range of proprietary microfluidic biomarker assays, including tests for blood cell adhesion, red blood cell deformability, whole blood rheology, and endothelialized microfluidics. These assays are designed to evaluate the effectiveness of emerging targeted and curative therapies, allowing clinicians to monitor patients' responses to treatment accurately.

xMD Diagnostics, based in Annapolis, Maryland, specializes in the biotechnology sector, focusing on molecular diagnostics tools that enhance research and clinical laboratory practices. Formerly known as Bay Resources Development Group, the company employs advanced high-throughput microdissection technology to aid in cancer diagnosis. Its innovative tools enable the isolation and enrichment of specific cells from biopsy and other specimen samples, facilitating downstream applications such as polymerase chain reaction (PCR), genomic and proteomic analyses, next-generation sequencing (NGS), and various molecular testing methods. This technology supports pathologists, oncologists, and other medical professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.

Tethys Research is a discovery company focused on developing high-value industrial enzymes and chemical entities. Founded to leverage expertise across diverse disciplines, Tethys addresses challenges that traditional high-throughput screening methods cannot effectively resolve. The company collaborates with various organizations to enhance the production and marketing of chemical products and processes, providing innovative solutions tailored to industry needs. Through its contract and partnership models, Tethys plays a significant role in advancing the capabilities of its clients in the chemical sector.

TheraCea Pharma is a biotechnology company based in Tucson, Arizona, that focuses on developing precision medicine for individuals with neurological disorders. As a spin-off from the University of Arizona, the company has developed and licensed advanced radiochemistry technology that facilitates high-efficiency and rapid fluorine-18 radiolabeling of biomolecules for both clinical and research applications. TheraCea Pharma's innovative approach includes creating treatments that address dyskinesia, particularly effects related to L-dopa, a common medication for Parkinson's disease. By providing new diagnostic agents, the company aims to enhance the detection of cancer and improve therapeutic outcomes for patients suffering from neurological conditions.

Kodikaz Therapeutic Solutions is a biotechnology company focused on developing targeted cancer therapies that aim to provide durable cures while minimizing side effects associated with traditional treatments. The company has created the Zip-Code™ Technology platform, a pioneering cell-specific delivery system designed for a wide range of gene therapy applications. This innovative platform leverages endogenous human mechanisms to avoid the complications associated with viral delivery methods. By translating previously unknown cell-recognition and genomic integration mechanisms, Kodikaz enables the development of cell-specific gene transfer technologies tailored for various cancers, including pancreatic, myeloma, and colorectal. Through its research and development efforts, the company generates both in-vitro and in-vivo data to support the advancement of curative therapies in oncology.

Frontier Bio Corporation is a biotechnology company based in Oakland, California, focused on developing and manufacturing advanced bioprinting technologies. Founded in 2018, the company specializes in creating lab-grown human tissues as an ethical alternative to animal studies. Its flagship product, the FLUX-1, is a 3D bioprinter that integrates conventional bioprinting methods with electro-hydrodynamic printing capabilities. This device enables the bioprinting of complex tissues such as skin, cartilage, and bone, and allows for applications in drug toxicity testing, tissue implants, drug screening, disease modeling, and prosthetics. By providing a means to produce human tissues with complete cell survivability, Frontier Bio aims to enhance the healthcare industry's ability to replace animal testing and address the organ transplant waitlist.

Nano PharmaSolutions specializes in enhancing the bioavailability of insoluble drugs through its proprietary nanoformulation technology. The company has developed an innovative phase-transition technology platform that significantly improves the solubility of BCS 2 and BCS 4 active pharmaceutical ingredients (APIs) without the need for excipients, which are typically used in traditional processes like spray-dry dispersion and emulsification. By vaporizing the API and depositing it onto a carrier molecule, Nano PharmaSolutions enables the production of nanoparticles that can be processed into various dosage forms. Additionally, the company focuses on delivering neurodegenerative therapeutics directly to the brain via an intranasal route, facilitating a rapid onset of action and enhancing safety profiles. Their pipeline includes treatments for conditions such as Parkinson's disease, peripheral neuropathy, and substance abuse disorders, positioning Nano PharmaSolutions as a key player in the field of nanomedicine.

Ancilia Biosciences is a biotechnology company focused on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components of the gut microbiome. By concentrating on enhancing healthy gut bacteria and their predatory phages, Ancilia develops therapeutic strains that can effectively combat chronic diseases in the fields of immunology and oncology. Additionally, the company is pioneering a new class of live biotherapeutics that allow for the precise targeting of phages or viruses known to induce lysis, thereby advancing treatment options in microbiome-related health conditions.

Hermes Life Sciences develops solutions to improve the accuracy and accessibility of blood testing at the point of care. The company was founded by Sasank Vemulapati.

HC Simulation, founded in 2011 and based in Canton, Mississippi, focuses on developing advanced products that utilize the HumMod engine to deliver high-quality simulations of human physiology. The company's offerings enable users to explore physiological interactions that may be difficult to observe in traditional settings. By providing a platform for realistic modeling, HC Simulation supports the ideation, development, and prediction processes for innovative medical devices and pharmaceuticals.

InSoma Bio integrates biology and materials science to solve problems in tissue engineering and regenerative medicine. It offers genetically engineer protein-based materials that can mimic the naturally found elastin found in extracellular tissues. The company also offers reconstructive plastic surgeries and injectable materials.

Stellate DNA, founded in 2020 and based in Cambridge, Massachusetts, specializes in proprietary DNA donor technology that enables the synthesis and production of single-strand DNA donors. The company's innovative platform employs clonal synthesis methods instead of traditional chemical synthesis, allowing for the customizable production of gene knock-in payloads. This approach ensures that Stellate DNA can achieve microgram to milligram scale production while maintaining well-controlled costs. Additionally, the technology supports medical professionals by ensuring minimal mutation rates and sequence uniformity, which are critical for various applications in genetic research and therapy.

Tacit Therapeutics is a biotechnology company focused on developing RNA-targeting treatments aimed at repairing mutated genes associated with devastating diseases. Founded in 2021 and located in South San Francisco, California, the company utilizes pre-existing components of human cells to create innovative and non-immunogenic approaches for gene modification. By offering a broadly applicable solution, Tacit Therapeutics enables biotechnology professionals to pursue effective treatments for genetic disorders that were previously deemed untreatable, thereby advancing the field of gene therapy.

Partillion Bioscience is an early-stage life science company focused on advancing single-cell analysis through its innovative platform. This novel nano vial technology enables the rapid compartmentalization and analysis of millions of single cells, facilitating the examination of biological functions, particularly concerning secreted proteins. By democratizing advanced single-cell assays, Partillion Bioscience aims to empower biotech laboratories and clients to develop more effective therapies for conditions such as cancer, autoimmune diseases, and infectious diseases.

Gate Scientific makes products that enable great research and improve healthcare decisions by bringing to market intuitive solutions that simplify complex problems. By bringing to market intuitive solutions that simplify complex problems, they allow for the latest technologies to benefit more people.

Kingdom Supercultures is a Brooklyn-based company established in 2019 that specializes in developing and producing microbial cultures for the food industry. The company focuses on reassembling nature's microbes into innovative combinations, allowing food manufacturers to create new varieties of food with enhanced benefits. Their product line includes Koji, a traditional Japanese ingredient used in miso, sake, and soy sauce, as well as microbial cultures for fermented sodas, beers, and plant-based dairy alternatives. Kingdom Supercultures employs an automated scientific platform that features a comprehensive biobank of Generally Recognized As Safe (GRAS) microbial strains and utilizes advanced algorithms to predict and assemble microbial communities. By providing functional ingredients and biopreservatives, the company aims to support healthy and sustainable food development across various industries, including food, beverage, personal care, and beauty.

SpheroFill is a drug delivery platform that specializes in creating innovative injectable tissue fillers, specifically designed to address age-related atrophy in the larynx. Utilizing a unique combination of solid, hollow, and porous-wall hollow glass microspheres along with biocompatible and bioactive matrices, SpheroFill enhances drug delivery for healthcare professionals. Its technology enables improved patient compliance by reducing dosing frequency and allows for oral formulations that current technologies cannot achieve. By focusing on the protection, delivery, and controlled release of active pharmaceutical ingredients, SpheroFill represents a significant advancement in the field of drug administration.

NellOne Therapeutics, Inc. is a regenerative medicine company based in Oak Ridge, Tennessee, focused on developing and commercializing protein therapeutics aimed at restoring cardiac muscle mass and function in patients recovering from myocardial infarction and congestive heart failure. The company was established in 2007 as a spin-out from the U.S. Department of Energy's Oak Ridge National Laboratory, where research led by Dr. Cymbeline Culiat identified the Nell1 gene's role in the formation of essential mammalian tissues and organs. NellOne is dedicated to translating these scientific discoveries into clinical applications, specifically by leveraging Nell1 protein therapeutics to rebuild cardiac muscle and improve patient outcomes following heart-related conditions.

Precision Theranostics is a biotechnology company established in 2019 and headquartered in Baltimore, Maryland. The company focuses on developing prognosis-based intervention strategies aimed at the early detection and treatment of fatal diseases. Its innovative platform estimates disease progression for respiratory diseases and age-related disorders, facilitating the creation of novel diagnostics, therapeutics, and prognosis-based therapies. By enabling healthcare professionals to provide timely diagnoses and interventions, Precision Theranostics seeks to enhance patient survival rates and prevent the development of chronic and life-threatening conditions.

Allegro 3D specializes in Digital Light Processing (DLP) printing technology, focusing on bioprinting applications. The company's platform is designed to accelerate the development of tissue models for drug screening and regenerative medicine. Allegro 3D provides high-precision and high-throughput manufacturing of biomedical devices, cell matrices, and human tissues. These products are used in cell culture, drug screening, therapeutics, and regenerative medicine, aiming to revolutionize healthcare innovations in these fields.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

FluidForm Bio is a biotechnology company focused on creating living human tissue to improve disease treatment. Utilizing its patented FRESH technology, the company employs 3D printing to construct tissue using cells, proteins, and no other materials. This innovative platform has been validated through partnerships with leading life science companies, enabling the production of high-quality tissue for various applications. FluidForm Bio's advanced techniques integrate breakthroughs in 3D printing, computational and synthetic biology, artificial intelligence, and materials science to deliver human tissue that closely resembles natural tissue. Established in 2018 and headquartered in Waltham, Massachusetts, FluidForm Bio aims to provide transformative therapies that offer better treatment options for patients in need.

Kepley BioSystems is a biotechnology company focused on developing innovative solutions to address critical challenges in ocean health and public safety. It specializes in ocean restorative technology aimed at combating the depletion of wild fish populations. Additionally, the company has created a life science platform that offers accurate methods for testing dangerous endotoxins. This platform enables advancements in healthcare by providing rapid and sensitive diagnostics for blood-borne pathogens, assisting physicians in the detection of bloodstream infections. Through its dual focus on environmental restoration and healthcare innovation, Kepley BioSystems aims to contribute significantly to both marine ecosystems and public health.

Sears Scientific specializes in developing advanced technologies and solutions designed to enhance the usability and accessibility of scientific equipment. Their products are tailored for use in microscopy and vacuum sciences, aiming to enable researchers to concentrate more on their scientific work rather than dealing with the complexities of instrumentation.

Amberstone Biosciences is a biotechnology company focused on discovering novel immunotherapies aimed at addressing challenging medical targets that traditional methods struggle to tackle. The company utilizes its proprietary microfluidics-powered AmberFlow drug-discovery platform, which allows for the analysis of single-cell function within a customizable microenvironment. This innovative approach, combined with the expertise of its team in immuno-oncology and single-cell assay biology, positions Amberstone to develop transformative therapeutic antibodies that cater to patients with unmet medical needs. Through creative partnerships and advanced technologies, Amberstone Biosciences seeks to overcome conventional limitations in therapeutic development, ultimately enhancing patient care and outcomes.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Founded in 2018, the company aims to transform the traditional methods of DNA production, which have remained largely unchanged for decades. Ansa's enzymatic approach promises to be faster, more accurate, and environmentally friendly compared to conventional chemical methods. This advanced technology facilitates the synthesis of gene-length oligonucleotides, enabling medical researchers to create synthetic genes efficiently. Ansa Biotechnologies' offerings are designed to support a wide range of applications in biological research, diagnostics, therapeutics, and biomanufacturing, ultimately accelerating innovation in the field of biotechnology.

DPX Technologies, founded in 2007 and headquartered in Columbia, South Carolina, specializes in patented pipette tip technology designed to enhance the quality of products used in complex chemical and biological analyses. The company's innovative solutions cater to automated liquid handling systems, facilitating the simplification and automation of intricate sample preparation processes. By providing efficient and customizable products, DPX Technologies enables scientists to implement streamlined laboratory workflows and methodologies, promoting greater efficiency in research and experimentation.

Cobio Diagnostics is a biotechnology company founded in 2016 and located in Golden, Colorado. The company specializes in developing diagnostics for bacterial identification and phenotypic antibiotic resistance testing. Utilizing a phage-based immunoassay, Cobio Diagnostics' technology allows for the rapid identification of specific bacterial species and the assessment of antibiotic susceptibility, achieving results in under five hours. This innovative approach provides a faster and more targeted alternative to conventional diagnostic methods, enabling healthcare providers to make prompt and informed decisions regarding antibiotic treatments for patients with bacterial infections.

Nabla Bio is a biotechnology company that specializes in the development of an autoreverse platform for the discovery of innovative protein variants. These proteins, which exhibit unique qualities, are engineered to create new medicines and enhance nutritional products. By leveraging insights gained from billions of natural proteins, Nabla Bio enhances these variants through extensive experimentation, allowing for advanced applications in both medical and industrial fields. The company's focus on complex measurements of protein function positions it as a leader in the pursuit of previously unattainable protein capabilities.

CytoRecovery, Inc. is a company specializing in the development of microfluidic technology for the recovery and testing of specific subpopulations of cancer cells from tumor biopsies and other biological samples. Founded in 2017 and based in Blacksburg, Virginia, CytoRecovery's technology allows cell biologists and life science researchers to quickly and effectively isolate rare, homogeneous, and viable cell subpopulations from diverse sources such as tissue and blood. This innovative approach enhances cell biology analytics by enabling the individual trapping and release of these rare cells for subsequent analysis, thereby advancing research in cancer and other diseases.

Florica Therapeutics is a biotechnology company founded in 2019 and based in Livermore, California. The company specializes in the development of exosome-based therapeutics aimed at extending lifespan and preventing diseases associated with aging. Florica's innovative therapeutics focus on delivering drugs to the brain and provide alternatives for treatment of life-altering conditions such as leukemia and Tay-Sachs disease. By leveraging exosome technology, the company aims to offer health institutions access to novel treatments that enhance patient longevity and quality of life.

Nano RED specializes in precision delivery technologies aimed at advancing RNA and immunotherapeutics for cancer treatment. The company develops innovative immunotherapy solutions that utilize liposomes, which are injected into the bloodstream. This approach allows for the direct release of cancer therapies into tumors and their surrounding environments, while also addressing the associated toxicity within the body. Through its cutting-edge technology, Nano RED seeks to enhance the effectiveness of cancer treatments and improve patient outcomes.

AthemBio is a biotechnology company focused on addressing significant challenges in bioprocessing, particularly in the manufacturing of biologics. The company develops innovative technologies and solutions aimed at combating pandemics and emerging threats from novel pathogens. AthemBio's offerings include advanced medical devices and bioprocessing systems designed to help healthcare institutions isolate and purify therapeutic antibodies. These capabilities are essential for treating COVID-19 and other pathogenic outbreaks, positioning AthemBio as a key player in the fight against infectious diseases.

CasTag Biosciences is a biotechnology company that specializes in cell biology and regenerative medicine, with a focus on enhancing the speed of endogenous protein analysis. The company develops Adeno-associated virus kits that leverage a two-vector, clustered regularly interspaced short palindromic repeats-based gene editing technique known as homology-independent universal genome engineering. This innovative approach enables researchers to modify entire panels of proteins within cells and tissues, facilitating the study of novel genes across various experimental models. By providing advanced tools for protein analysis, CasTag Biosciences aims to accelerate scientific discovery and enhance understanding in the field of genetics.

Ramona is a biotechnology company that manufactures advanced microscopy toolsets designed for cellular-level research. Their core product is a microscope equipped with custom control electronics and an array of micro-cameras, enabling it to capture vast amounts of image data across large areas synchronously. This technology offers researchers a broader field of view and the ability to observe cellular dynamics in motion, facilitating more informed decision-making and accelerating scientific discoveries.

Silvec Biologics specializes in developing RNA therapies aimed at treating and preventing diseases in trees, vines, and bushes without resorting to genetic modification. The company employs innovative RNA-based molecules that function by introducing virus-like RNA into tree veins, targeting and eliminating harmful viral and fungal pathogens. This approach not only safeguards the health of these plants but also supports food growers in maintaining abundant and diverse food supplies. By focusing on the preservation of natural resources, Silvec Biologics contributes to the sustainability of ecosystems and food systems, ultimately benefiting future generations.

iReprogram is a cell regeneration laboratory based in Ann Arbor, Michigan, established in 2017. The company focuses on advancing personalized medicine through innovative cell reprogramming technology. By utilizing a high-fidelity prototype computational tool, iReprogram generates transcription factor recipes that facilitate cellular trans-differentiation, particularly for cancer treatment. This technology aims to enhance the effectiveness of cancer therapies, ultimately allowing patients to benefit from more tailored and effective treatment options.

Progenitor MDX is a biotechnology company focused on developing advanced cellular immunotherapy technologies and innovative solutions for managing COVID-19 infections. The company offers a comprehensive approach that includes testing and actionable infection management plans, aimed at providing reassurance to communities. In addition to its COVID-19 management solutions, Progenitor MDX specializes in cellular reprogramming, utilizing a streamlined method that incorporates all Yamanaka factors into a single vector. This technology enables the creation of allogeneic off-the-shelf CAR constructs from various cell sources, facilitating the efficient insertion of multiple genetic elements. By enhancing the industrial workflows for producing engineered cell therapies, Progenitor MDX plays a critical role in advancing immune-oncology and the development of new therapeutic options.

GMJ Technologies is a Seattle-based company founded in 2018 that specializes in the development of microanalytical technologies tailored for biopharmaceutical and biomedical applications. The company focuses on creating robust analytical tools and integrated technologies that aim to enhance proteomics and streamline analytical workflows for protein-based biologics. By innovating in research, development, and manufacturing processes, GMJ Technologies seeks to revolutionize the analytical landscape within the biopharmaceutical sector.

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company specializes in the development and commercialization of silk biomaterial technologies, particularly the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapeutics. This innovative sustained release patch technology enhances vaccine administration by simulating a natural infection, promoting a robust and prolonged immune response, thereby improving vaccine effectiveness. Additionally, Vaxess’s MATRIX formulation and drying platform creates thermostable vaccines, therapeutics, and diagnostic products that do not require refrigeration, making them suitable for distribution in low-resource settings. Through these advanced solutions, Vaxess aims to improve patient outcomes in oncology care and infectious diseases while reducing treatment burdens for healthcare practitioners.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the underlying causes of these conditions, particularly immune evasion and drug resistance. Its primary focus is on creating market-disruptive biologics for recurrent and drug-resistant cancers, specifically addressing the needs of patients with recurrent metastatic breast cancer. By concentrating on these critical areas, Creative BioTherapeutics seeks to enable medical professionals to provide effective treatments for both adult and childhood cancers, potentially leading to tumor regression and improved patient outcomes.

Ernest Pharmaceuticals is a biotechnology company founded in 2016 and based in Hadley, Massachusetts. The company specializes in developing innovative bacterial therapeutics aimed at treating cancer. Its unique approach involves the use of programmed bacteria that are engineered with synthetic techniques to deliver intracellular macromolecules. These motile bacteria actively penetrate tumor tissue, which enhances their ability to target metastatic disease and inoperable tumors. By focusing on this novel method of cancer treatment, Ernest Pharmaceuticals seeks to advance therapeutic options for patients facing difficult-to-treat malignancies.

Optimeos Life Sciences is a biotechnology company focused on developing encapsulation technology-based drugs that utilize biologics, peptides, and RNA for disease treatment. The company addresses significant challenges associated with the delivery of biologics and peptide therapeutics by providing solutions that protect these agents and ensure their targeted delivery within the body. This innovative approach facilitates sustained delivery of peptide therapeutics through the use of nano-composite microparticles, thereby enhancing the efficacy of treatments and improving patient outcomes.

Inanovate Inc. is a biotechnology company that specializes in the development of protein screening and analysis technologies for the life sciences industry. Founded in 2006 and headquartered in Sioux Falls, South Dakota, with an additional office in Raleigh, North Carolina, Inanovate offers its flagship product, Bio-ID, a protein screening biochip platform. This platform provides sensitive real-time kinetic data for multiple protein interactions, facilitating applications in protein research, drug development, quality control, biomarker profiling, and clinical diagnostics. The company also offers a range of services, including biomarker discovery and validation programs, nano-particle surface technology for protein immobilization, and various protein micro-array services. Inanovate serves a diverse clientele, including researchers, clinical centers, and biotech and pharmaceutical companies, with operations extending to the United States and the United Kingdom.

Think Bioscience is a company focused on advancing synthetic biology to enhance the development of medicines. It employs innovative technology to encode complex molecular objectives within microbial hosts, facilitating the identification, construction, and evolution of small molecules. By leveraging living systems, Think Bioscience aims to transform the drug discovery process, providing medical researchers with powerful tools to create better therapeutic solutions. The company's approach represents a significant evolution in the field of synthetic biology, positioning it as a leader in the quest for improved medicinal outcomes.

Cornerstone Genomics, established in 2017 and based in Frederick, Maryland, specializes in providing expert guidance on the application of genomic tools in human disease research, biomedicine, veterinary sciences, and wildlife conservation. The company operates a biotechnology platform that houses proprietary DNA and protein sequence databases, along with applications designed to meticulously filter, annotate, and predict the functional impact of genetic variants. This precision enables researchers to accurately identify disease-causing genetic changes, facilitating the development of targeted therapies and gene therapies for inherited diseases.

TEGA Therapeutics, Inc. is a biotechnology company focused on developing glycoscience-related technologies aimed at treating life-threatening diseases. Based in La Jolla, California, the company utilizes glycoside-enhanced delivery systems to improve the administration of enzyme replacement therapies for lysosomal storage disorders, addressing significant unmet medical needs. TEGA also specializes in the recombinant production of heparan sulfate and heparin. The company's innovative approach seeks to facilitate the delivery of critical treatments across the blood-brain barrier, thereby enhancing the quality of life for patients facing severe health challenges. Founded in 2013, TEGA is committed to leveraging scientific insights and rigorous methodologies to support advancements in pharmaceutical therapies.

Seven Biosciences provides drug discovery platforms for G-protein coupled receptors. The company, based in Davis, California, was founded by Grace Mizuno and Lin Tian.

Bondwell Technologies is a biotechnology company focused on developing biomaterial-based technologies that harness the natural capabilities of proteins and molecular tools. The company creates innovative materials with diverse structural, mechanical, and functional properties tailored for various applications. These applications include tissue engineering, biosensing, drug delivery, and photonics. By optimizing its technologies, Bondwell aims to facilitate advancements across multiple fields such as energy, environment, and medicine, thereby contributing to significant research and development efforts in these critical areas.

Ionica Sciences, Inc. is a diagnostic company based in Ithaca, New York, founded in 2013. It specializes in developing a spectroscopy-based diagnostic platform that employs surface enhanced Raman scattering (SERS) technology. This innovative approach is designed to diagnose a range of diseases, including vector-borne, sexually transmitted, and neurological conditions. Ionica Sciences focuses on creating in-vitro diagnostic assay tests, particularly for Lyme disease and other infectious diseases, allowing medical professionals to detect biologically relevant targets such as pathogens and hormones. By providing accurate and rapid diagnostic solutions, the company aims to enhance clinical decision-making, reduce unnecessary antibiotic usage, and lower healthcare costs associated with misdiagnoses.

FloBio is a Philadelphia-based company founded in 2017 that specializes in point-of-care diagnostics for assessing bleeding risk through real-time blood analysis. The company has developed an innovative fluidic-based diagnostic platform that leverages microfluidic technology to measure blood clotting function under physiologic conditions. This platform delivers rapid and actionable measurements, allowing clinicians to make informed decisions and personalize patient management during critical moments. By focusing on enhancing the accuracy and immediacy of blood analysis, FloBio aims to improve outcomes in medical situations where bleeding risk is a significant concern.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

Ascribe Bioscience, established in 2017 and based in Ithaca, New York, specializes in developing crop protection products. Their primary focus is creating seed treatments that bolster plants' innate defenses against pathogens like Rhizoctonia, without leaving a negative environmental footprint. The company's innovative approach involves studying the molecular interactions between microbes and plants to identify immunity-activating signaling molecules.